The Weinbach Group’s Post

🔍 Need to accelerate your drug discovery program? Let us help you. BPS Bioscience Inc. offer screening services to quickly identify potential therapeutics, predict potency, and narrow down large pools of candidates to much smaller ones. Additionally, cell-based screening services are also available for a more comprehensive view of the biological context and resulting cellular responses. Follow the link for more information 👇 https://lnkd.in/ei9wwpMA #DrugDiscovery #Bioscience

Check out our article about overcoming the development challenges of PEGylated therapeutics 👇🏻

Researchers, how would you propose to progress drug delivery systems for the posterior inner eye segment? Your solutions should ensure sustained release over at least three months for diverse therapeutics ranging from low molecular weight compounds to complex molecules. Learn more on our open science platform #opnMe: https://lnkd.in/gEDjfkdd

Providing a snapshot of FDB's PEGylation experience and capacity - from PD to commercial scale.

Today, we provided our third quarter 2024 financial and corporate update. Learn about advances made and upcoming milestones across our pipeline of multiple therapeutics targeting novel biology in the chromatin regulatory system: https://bit.ly/3AocMDR #biotechnology

EDIT: all sessions are now available on demand! Speaker Spotlight Round Two! With a week to go and I'd like to shine a light on the rest of our amazing speakers whose talks will be broadcast on Dec. 11th. They will then join me for a live joint Q&A on Dec. 12th, 3:00 PM CET / 9 AM EST Mary Murphy - Automated Production for Cell and Gene-based Therapeutics Vishwanath Hebbi, PhD - Material Traceability In Continuous Manufacturing Kurt Boenning - Enabling technologies and automation for process intensification #Bioprocessing #CGT #Biopharma #ContinuousManufacturing #ContinuousBioprocessing #Automation

WATCH: Cizzle Biotechnology plc USA and Canada Agreement Major Milestone Dr. Alan Syms, discusses the significance of this partnership, detailing the financial benefits such as a guaranteed royalty stream and a $2.4 million upfront payment over 30 months, which represents a substantial revenue stream for the company. Additionally, Alan outlines the savings from not conducting the clinical trials themselves and the partnership’s role in supporting development work in the UK. He touches on Cizzle’s focus on the US market due to its large size and unmet need for simple blood tests for lung cancer screening, the company’s licensing business model, and its future product development plans and market strategies both in North America and globally and the steps the company will be taking over the short to medium term. #CizzleBiotech #LungCancer #EarlyDetection #BloodTest #LungCancerTest #Investing #CizzleBio #NorthAmerica #Stocks #Shares #CizzleBioInc

The A-Alpha team is excited to participate in the Festival of Biologics Annual Meeting in San Diego next week! During the meeting, we will share our latest work on applying AlphaSeq and AlphaBind for immunocytokine engineering.     In his talk, A-Alpha Co-Founder and CEO David Younger will delve into the applications of our platforms to engineer immunocytokine therapeutics using high-throughput experiments and machine learning.  A-Alpha Principal Scientist Emily Engelhart will further present a poster on how our platforms enable the discovery and optimization of highly specific cis-targeting immunocytokines. If you’re attending, catch David’s talk and visit Emily’s poster to learn more.    #biotech #immunocytokines #FestivalofBiologics  

Extracellular #vesicles: setting-up the path to IND with advanced characterization packages #Extracellularvesicles (#EVs) are a promising delivery vehicle for various #biotherapeutics. #Advancedcharacterization is crucial for developing EV-based therapeutics, however, it is also challenging due to their diverse cargo and sizes. Next month, Lonza’s Davide Zocco (Director, Site Management) will discuss the intricacies of producing EV-based therapies, emphasizing the importance of precise analytics and process design to maintain control over product quality throughout #clinicaldevelopment Register for this upcoming #webinar below:

Extracellular #vesicles: setting-up the path to IND with advanced characterization packages #Extracellularvesicles (#EVs) are a promising delivery vehicle for various #biotherapeutics. #Advancedcharacterization is crucial for developing EV-based therapeutics, however, it is also challenging due to their diverse cargo and sizes. Next month, Lonza’s Davide Zocco (Director, Site Management) will discuss the intricacies of producing EV-based therapies, emphasizing the importance of precise analytics and process design to maintain control over product quality throughout #clinicaldevelopment Register for this upcoming #webinar below: